The Cystic Fibrosis Foundation invested $3.5 million in Pulmocide as part of the CF Foundation’s Lung Transplant InitiativeFunding supports prophylaxis…
Robinson’s expertise in development and commercialization adds to the clinical and commercial experience of newly appointed management teamGAINESVILLE, Fla. and CAMBRIDGE,…
-- RareStone to seek marketing authorization for IMCIVREE to treat obesity due to biallelic POMC, PCSK1 and LEPR deficiencies and…
MIAMI, Dec. 06, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces that Director Richard A. Lerner, M.D. passed…
PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the…
Stacey Stevens Appointed as President and CEO and will Join the Board of Directors in 2022, Michael Klein to remain…
AUSTIN, Texas, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing…
NGM entered into a clinical trial collaboration and supply agreement with Merck to evaluate the potential of NGM707 in combination…
HAUPPAUGE, N.Y., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious…
HLHS is a rare congenital heart defect that affects approximately 1,000 babies in the U.S. per yearOrphan Drug Designation confers…